Crown Laboratories Completes Acquisition of Revance Therapeutics
Crown Laboratories, a privately held skincare company and Hildred Capital portfolio company, has completed its acquisition of Revance Therapeutics (NASDAQ: RVNC), a biotechnology company focused on aesthetic and therapeutic healthcare innovations. The acquisition aims to strengthen Crown's position in the skincare and aesthetics industry by combining both companies' resources and capabilities.
Crown's CEO Jeff Bedard emphasized that the merger enhances their ability to deliver innovative solutions across the three pillars of facial aesthetics – relax, restore, and regenerate. The combined entity will maintain Revance's partnership with Teoxane for the RHA® Collection in the U.S. market.
Crown Laboratories, una società di skincare a capitale privato e parte del portafoglio di Hildred Capital, ha completato l'acquisizione di Revance Therapeutics (NASDAQ: RVNC), un'azienda biotecnologica focalizzata su innovazioni sanitarie estetiche e terapeutiche. L'acquisizione mira a rafforzare la posizione di Crown nel settore della skincare e dell'estetica, combinando le risorse e le capacità di entrambe le aziende.
Il CEO di Crown, Jeff Bedard, ha sottolineato che la fusione aumenta la loro capacità di offrire soluzioni innovative nei tre pilastri dell'estetica facciale: rilassare, ripristinare e rigenerare. L'entità combinata manterrà la partnership di Revance con Teoxane per la RHA® Collection nel mercato statunitense.
Crown Laboratories, una empresa de cuidado de la piel de propiedad privada y parte del portafolio de Hildred Capital, ha completado su adquisición de Revance Therapeutics (NASDAQ: RVNC), una empresa biotecnológica enfocada en innovaciones en salud estética y terapéutica. La adquisición tiene como objetivo fortalecer la posición de Crown en la industria del cuidado de la piel y la estética combinando los recursos y capacidades de ambas empresas.
El CEO de Crown, Jeff Bedard, enfatizó que la fusión mejora su capacidad para ofrecer soluciones innovadoras en los tres pilares de la estética facial: relajar, restaurar y regenerar. La entidad combinada mantendrá la asociación de Revance con Teoxane para la Colección RHA® en el mercado estadounidense.
Crown Laboratories는 민간 skincare 회사이자 Hildred Capital의 포트폴리오 회사로, Revance Therapeutics (NASDAQ: RVNC)의 인수를 완료했습니다. 이는 미용 및 치료 건강 혁신에 중점을 둔 생명공학 회사입니다. 이번 인수는 두 회사의 자원과 역량을 결합함으로써 Crown의 스킨케어 및 미용 산업 내 입지를 강화하는 것을 목표로 합니다.
Crown의 CEO인 Jeff Bedard는 이번 합병이 얼굴 미용의 세 가지 기둥인 이완, 복원, 재생을 통해 혁신적인 솔루션을 제공할 수 있는 능력을 향상시킨다고 강조했습니다. 결합된 회사는 미국 시장에서 RHA® 컬렉션을 위한 Revance와의 파트너십을 유지할 것입니다.
Crown Laboratories, une entreprise de soins de la peau détenue par des privés et faisant partie du portefeuille d'Hildred Capital, a finalisé l'acquisition de Revance Therapeutics (NASDAQ: RVNC), une entreprise biopharmaceutique axée sur les innovations en soins esthétiques et thérapeutiques. L'acquisition vise à renforcer la position de Crown dans l'industrie des soins de la peau et de l'esthétique en combinant les ressources et les capacités des deux entreprises.
Le PDG de Crown, Jeff Bedard, a souligné que la fusion améliore leur capacité à offrir des solutions innovantes autour des trois piliers de l'esthétique faciale : détendre, restaurer et régénérer. L'entité combinée maintiendra le partenariat de Revance avec Teoxane pour la Collection RHA® sur le marché américain.
Crown Laboratories, ein privat geführtes Hautpflegeunternehmen und Teil des Portfolios von Hildred Capital, hat die Übernahme von Revance Therapeutics (NASDAQ: RVNC), einem Biotechnologieunternehmen, das sich auf ästhetische und therapeutische Gesundheitsinnovationen konzentriert, abgeschlossen. Die Übernahme zielt darauf ab, die Position von Crown in der Hautpflege- und Ästhetikbranche zu stärken, indem die Ressourcen und Fähigkeiten beider Unternehmen kombiniert werden.
Der CEO von Crown, Jeff Bedard, betonte, dass die Fusion ihre Fähigkeit verbessert, innovative Lösungen in den drei Säulen der Gesichtsästhetik - entspannen, wiederherstellen und regenerieren - anzubieten. Das kombinierte Unternehmen wird die Partnerschaft von Revance mit Teoxane für die RHA®-Kollektion auf dem US-Markt aufrechterhalten.
- Strategic acquisition strengthens Crown's market position in aesthetics
- Maintains valuable partnership with Teoxane for RHA® Collection distribution
- Integration creates comprehensive portfolio across facial aesthetics segments
- Revance will be delisted from NASDAQ following the acquisition
Insights
The completion of Revance's acquisition by Crown Laboratories represents a pivotal shift in the aesthetics and skincare industry landscape. This strategic consolidation creates a formidable entity that encompasses the complete spectrum of facial aesthetics - relax, restore and regenerate - positioning Crown as a potential dominant force in the global market.
The transaction's significance extends beyond mere market consolidation. For Revance shareholders, this marks the end of their public market journey, while Crown gains access to Revance's innovative biotechnology portfolio and established partnerships, particularly the valuable relationship with Teoxane for the RHA® Collection in the U.S. market. The integration of Revance's assets into Crown's portfolio could accelerate product development timelines and expand market reach through Crown's established distribution channels.
The deal's timing is particularly strategic, coming at a period of increasing demand for aesthetic treatments and skincare solutions. Crown's backing by Hildred Capital suggests strong financial support for future growth initiatives and potential market expansion. The combined entity's enhanced R&D capabilities and comprehensive product portfolio could create significant barriers to entry for competitors while potentially accelerating innovation in the aesthetics space.
However, the success of this acquisition will largely depend on Crown's ability to execute a smooth integration while maintaining Revance's existing partnerships and innovation pipeline. The retention of key personnel and preservation of Revance's intellectual property assets will be important factors in realizing the full value of this transaction.
Jeff Bedard, Founder and Chief Executive Officer of Crown commented, “We are excited to officially welcome Revance to the Crown family. This acquisition strengthens our leadership position and enhances our ability to deliver innovative solutions to customers, with what we believe is a comprehensive portfolio that represents the three pillars of facial aesthetics – relax, restore, and regenerate – and we will support these offerings with a highly trained and experienced sales force. We are well-positioned to become a global leader in the aesthetics and skincare industry and will leverage our combined resources to create long-term value for our stakeholders.”
On behalf of Hildred, Co-Founders and Managing Partners Andrew Goldman and David Solomon said, “We are thrilled to celebrate the successful completion of this transaction and to commence the integration of two innovative companies that we believe will create a leading player in the dynamic skincare and aesthetics markets. Crown remains committed to providing healthcare providers and aesthetic practices with outstanding science-based products. We are excited to bring together Revance’s and Crown’s aesthetic offerings, and we look forward to continuing Revance’s relationship with Teoxane to grow the RHA® Collection by Teoxane in the
Additional details on the deal closing can be found in the press release HERE.
About Crown
Crown, a privately held, fully integrated global skincare company, is committed to developing and providing a diverse portfolio of aesthetic, premium and therapeutic skincare products that improve the quality of life for its consumers throughout their skincare journey. An innovative company focused on skin science for life, Crown's unyielding pursuit of delivering therapeutic excellence and enhanced patient outcomes is why it has become a leader in Dermatology and Aesthetics. Crown has been listed on the Inc. 5000 Fastest Growing Privately Held Companies List for eleven years and has expanded its distribution to over 50 countries. For more information, visit www.crownlaboratories.com.
The "Crown" logo, PanOxyl and Blue Lizard are registered trademarks of Crown Laboratories, Inc. SkinPen and StriVectin are registered trademarks of Bellus Medical, LLC and StriVectin Operating Company, Inc., respectively.
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers. RHA® technology is proprietary to and manufactured in
“Revance,” the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA are trademarks of TEOXANE SA.
About Hildred Capital
Hildred Capital is a healthcare-focused private equity firm that specializes in operationally intensive, control-oriented investments in lower middle-market companies. Hildred partners with innovative and growth-oriented management teams to build high quality businesses. The Hildred team possesses extensive experience across the healthcare industry, and seeks to leverage its unique blend of strategic, financial, commercial and operational acumen to drive strategic growth and create value for its portfolio companies and investment partners. Hildred currently has more than
View source version on businesswire.com: https://www.businesswire.com/news/home/20250207314086/en/
Media Contacts:
Crown
Alecia Pulman
ICR
Crown@icrinc.com
Hildred Capital
Mike Geller
Prosek Partners
mgeller@prosek.com
Source: Hildred Capital
FAQ
What are the financial terms of Crown Laboratories' acquisition of Revance (RVNC)?
Will Revance (RVNC) continue trading on NASDAQ after the Crown acquisition?
What happens to the RHA® Collection partnership after Crown's acquisition of RVNC?
What are the three pillars of facial aesthetics mentioned in Crown's acquisition of RVNC?
